This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nahata, M. C. Articles by Foulds, G. Search for Related Content PubMed PubMed Citation Articles by Nahata, M. C. Articles by Foulds, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 08 1995, 1875-1877, Vol 39, No. 8
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Pharmacokinetics of azithromycin in pediatric patients with acute otitis media

MC Nahata, KI Koranyi, DR Luke and G Foulds
College of Pharmacy, Ohio State University, Columbus 43210, USA.

The objective of our study was to characterize the pharmacokinetics of azithromycin after the oral administration of multiple doses in suspension to children with acute otitis media. Thirteen children (ranging in age from 7.5 months to 5 years) received a single oral dose of 10 mg of azithromycin per kg of body weight on day 1 followed by single daily doses of 5 mg/kg on days 2 to 5. Each child fasted overnight before receiving the final dose on day 5. Multiple blood samples were collected after the last dose. Concentrations of azithromycin in serum were measured by a specific high-performance liquid chromatography-mass spectrometry method. The means and standard deviations for the maximum concentration of azithromycin in serum, the time to maximum concentration of azithromycin in serum, the area under the concentration-time curve (from 0 to 24 h), and the elimination half- life were 224 +/- 120 ng/ml, 1.8 +/- 0.4 h, 1,841 +/- 651 ng.h/ml, and 31.6 +/- 6.6 h, respectively. Concentrations in serum (means +/- standard deviations) at 0 h (predose) and at 24, 48, and 72 h after the final dose were 51 +/- 26, 47 +/- 21, 27 +/- 17, and 17 +/- 13 ng/ml, respectively. Thus, the once-daily administration of azithromycin resulted in sustained systemic exposure to the drug. The drug dosage regimen used in this study should lead to tissue drug concentrations exceeding the MICs for common pathogens.

This article has been cited by other articles:

• Law, C., Amsden, G. W (2004). Single-Dose Azithromycin for Respiratory Tract Infections. The Annals of Pharmacotherapy 38: 433-439 [Abstract] [Full Text]  
• Babl, F. E., Pelton, S. I., Li, Z. (2002). Experimental Acute Otitis Media Due to Nontypeable Haemophilus influenzae: Comparison of High and Low Azithromycin Doses with Placebo. Antimicrob. Agents Chemother. 46: 2194-2199 [Abstract] [Full Text]  
• Ngo, L. Y., Yogev, R., Dankner, W. M., Hughes, W. T., Burchett, S., Xu, J., Sadler, B., Unadkat, J. D. (1999). Pharmacokinetics of Azithromycin Administered Alone and with Atovaquone in Human Immunodeficiency Virus-Infected Children. Antimicrob. Agents Chemother. 43: 1516-1519 [Abstract] [Full Text]